Alexis Chesrow, MD
Urology · New Orleans, LANPI 1427207281
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 44.7% of the total. Reporting peaked in 2020 at $8,022 and has fallen 90.6% since, to $756 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $94.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Coloplast$3K
- Medtronic$2K
- Boston Scientific$1K
- Axonics, Inc.$1K
- Astellas Pharma US Inc$347
- plus $2K from 25 others
Across 9 payments — averaging $2163.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$12K
- Medtronic$7K
What the payments were for
- Travel & lodging$4,13124%
- Food & beverage$6,94140%
- Education$6,16536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $7,707 |
| Coloplast | 35 | $2,540 |
| Medtronic(2 entities) | 32 | $2,433 |
| Boston Scientific | 24 | $1,258 |
| Axonics, Inc. | 15 | $1,221 |
| Astellas Pharma US Inc | 15 | $347 |
| Endo Pharmaceuticals Inc. | 5 | $251 |
| Procept Biorobotics Corporation | 1 | $171 |
| Urogen Pharma, Inc. | 5 | $167 |
| Bluewind Medical | 3 | $159 |
| Cycle Pharmaceuticals Inc | 1 | $122 |
| Teleflex LLC | 3 | $104 |
| Myovant Sciences Inc. | 5 | $91 |
| Progenics Pharmaceuticals, Inc. | 1 | $87 |
| 180 Medical, Inc. | 4 | $85 |
| Koelis Inc. | 1 | $79 |
| KARL Storz Endoscopy-america | 1 | $65 |
| Antares Pharma, Inc. | 1 | $50 |
| Urovant Sciences Inc | 3 | $50 |
| Endo USA, Inc. | 2 | $46 |
| AbbVie | 2 | $38 |
| Merck | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Caldera Medical, Inc | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Mission Pharmacal Company | 1 | $13 |
| Smith+Nephew | 1 | $13 |
| Pfizer | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,532
- INTERSTIM$1,627
- ALTIS$1,123
- TITAN$584
- Axonics r-SNM System$583
- Bulkamid$583
- Axonics$236
- UPSYLON$221
- AquaBeam Robotic System$171
- RESTORELLE$142
- AMS 700$131
- REVI$130
- Venxxiva$122
- Moses 550 D\F\L$117
- XIAFLEX$115
- Saffron$109
How this compares
$17,237 in reported general payments places this provider in the 90th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 36 | $19,345 |
| MyrbetriqMirabegron | 24 | $14,589 |
| Estradiol | 64 | $4,551 |
| Tamsulosin Hcl | 35 | $193 |
| Finasteride | 14 | $100 |
| Fluconazole | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $347 | $14,58924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.